Expertise in
59
conditions

Dr. Ying Zhuo

Hematology | Hematology Oncology
7360 West Deschutes Avenue, 
Kennewick, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
59
conditions
7360 West Deschutes Avenue, 
Kennewick, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ying Zhuo is a Hematologist and a Hematologist Oncology provider in Kennewick, Washington. Dr. Zhuo is highly rated in 59 conditions, according to our data. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Familial Wilms Tumor 2, Chromophobe Renal Cell Carcinoma, and Paget Disease of the Breast. Dr. Zhuo is currently accepting new patients.

Her clinical research consists of co-authoring 92 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Prosser Memorial Hospital
Trios Health
Kadlec Regional Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

7360 West Deschutes Avenue, Kennewick, WA 99336

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

92 Total Publications

Allosteric Activation of Cas12a via PAM Topological Engineering for Direct and Rapid Detection of Nucleases.
Allosteric Activation of Cas12a via PAM Topological Engineering for Direct and Rapid Detection of Nucleases.
Journal: Angewandte Chemie (International ed. in English)
Published: July 16, 2025
Similar Doctors
Expertise in
62
conditions
Dr. Basir U. Haque
Hematology Oncology | Hematology
Expertise in
62
conditions
Dr. Basir U. Haque
Hematology Oncology | Hematology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (0.1 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Basir Haque is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Haque is highly rated in 62 conditions, according to our data. His top areas of expertise are Lynch Syndrome, Thrombocytopenia, Anal Cancer, and Paget Disease of the Breast. Dr. Haque is currently accepting new patients.

Expertise in
66
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Hematology
Expertise in
66
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Hematology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (0.1 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Gamboa is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Gamboa is highly rated in 66 conditions, according to our data. His top areas of expertise are Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), Lynch Syndrome, and Paget Disease of the Breast. Dr. Gamboa is currently accepting new patients.

Expertise in
76
conditions
Dr. Rangaswamy A. Chintapatla
Hematology Oncology | Oncology
Expertise in
76
conditions
Dr. Rangaswamy A. Chintapatla
Hematology Oncology | Oncology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (0.1 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rangaswamy Chintapatla is a Hematologist Oncology specialist and an Oncologist in Kennewick, Washington. Dr. Chintapatla is highly rated in 76 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Myelodysplastic Syndrome (MDS), and Familial Colorectal Cancer. Dr. Chintapatla is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhuo's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 44 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile